Grabar Law Office Investigates Claims on Behalf of Shareholders of Insulet Corporation (PODD)

Philadelphia, Pennsylvania--(Newsfile Corp. - July 3, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Insulet Corporation (NASDAQ: PODD).

WHAT IS THIS INVESTIGATION ABOUT? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Insulet Corporation (NASDAQ: PODD) shares prior to February 21, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/insulet-shareholder-investigation/, contact Joshua Grabar at [email protected], or call 267-507-6085. Alternatively, if you purchased Insulet shares between February 21, 2025 and May 26, 2026, you can participate in the class action.

WHY? As alleged in a recently filed federal securities fraud class action complaint, Insulet Corporation (NASDAQ: PODD), through certain of its executives, violated federal securities laws by making false and/or misleading statements and/or failed to disclose that: (i) Insulet's manufacturing controls and procedures were defective; (ii) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.

The truth began to emerge on March 12, 2026, when Insulet disclosed that it had "initiated a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods after identifying a manufacturing issue through its ongoing product monitoring." Then, on May 26, 2026, Insulet disclosed the "initat[ion]" of another "voluntary Medical Device Correction" (the "May 2026 MDC"), this time "for specific lots of Omnipod® 5, Omnipod Dash®, and Omnipod® Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery."

WHAT CAN YOU DO NOW? If you purchased Insulet Corporation (NASDAQ: PODD) shares prior to February 21, 2025, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/insulet-shareholder-investigation/, contact Joshua Grabar at [email protected], or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Alternatively, if you purchased Insulet shares between February 21, 2025 and May 26, 2026, you can participate in the class action.

#Insulet, #PODD $PODD

Attorney Advertising Disclaimer

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/303926

You May Also Be Interested In

• Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Insulet Corporation (NASDAQ: PODD); Photronics, Inc. (NASDAQ: PLAB); and Via Transportation, Inc. (NYSE: VIA): Grabar Law Office is Inv
• Es Bancshares, Inc. (ESBS) Tops Q2 EPS by 13c
• Northrop Grumman wins $1.2B Navy contract for E-2D aircraft